Skip to content
Lower risk Drug recall · FDA · Published May 14, 2020

InvaGen Gabapentin Tablets Recall: Impurity Risk in Long-Term Storage

InvaGen Pharmaceuticals recalls 600mg Gabapentin tablets due to impurity failure in long-term stability testing. Affected lots may pose risks if stored beyond expiration.

🇺🇸 FDA recall #D-1272-2020DrugInvaGen ›
Take action

Contact the company

Recalling firmInvaGen Pharmaceuticals, Inc.7 Oser Ave · Hauppauge, NY 11788-3811
✎ GovInfoNow plain-language explainer

InvaGen Pharmaceuticals is recalling 600mg Gabapentin tablets that failed impurity tests during long-term stability testing. This could mean the tablets might contain harmful substances if stored past their expiration date. Read more at govinfonow.com/recall/37119-invagen-gabapentin-tablets-recall-impurity-risk-in-long-term-storage.

Source Summary by GovInfoNow · govinfonow.com/recall/37119-invagen-gabapentin-tablets-recall-impurity-risk-in-long-term-storage · Updated October 5, 2026 · FDA enforcement record: FDA #D-1272-2020

Cite this page

“InvaGen Gabapentin Tablets Recall: Impurity Risk in Long-Term Storage.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/37119-invagen-gabapentin-tablets-recall-impurity-risk-in-long-term-storage. Based on FDA recall #D-1272-2020 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1272-2020%22&limit=1).

InvaGen Pharmaceuticals, Inc. voluntarily recalled Gabapentin Tablets USP, 600 mg, manufactured for Exelan Pharmaceuticals, Inc., due to failed impurity specifications, the FDA announced on May 14, 2020. The recall affects 2,202 bottles distributed nationwide.

How to tell if you have it

  • Brand: InvaGen
  • Product: Gabapentin Tablets USP, 600 mg, Rx Only, 500-count bottle
  • NDC: 76282-405-05
  • Lot #: NB900413
  • Expiration: 12/2020
  • Manufacturer: InvaGen Pharmaceuticals, Inc., Hauppauge, NY 11788
  • Distributor: Exelan Pharmaceuticals, Inc., Lawrenceville, GA 30046

The hazard

The recall was initiated because the product failed Impurity A test at the 12-month long-term stability testing. The FDA classified this as a Class III recall.

Context

GovInfoNow's records show InvaGen Pharmaceuticals, Inc. has had 7 other recalls on record since March 5, 2018. Other recent recalls of similar products include Somerset Therapeutics Dexamethasone Injection Recall (Feb. 4, 2026) and Sagent Busulfan Injection Recall (May 4, 2026).

How to tell if you have this one

Check for the NDC code 76282-405-05 on the bottle. The specific lot number NB900413 was manufactured in Lawrenceville, GA and expires December 2020.

  • Brand
    InvaGen
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Product Details

    Look for the NDC code 76282-405-05 and lot number NB900413 on the bottle.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the U.S.” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 4 months after the firm started it.

1. Firm started the recall: May 14, 202012. FDA classified it Class III: May 21, 202023. Published in FDA’s Enforcement Report: May 27, 202034. FDA terminated the recall: Aug 31, 202042020
  1. Firm started the recall
  2. FDA classified it Class III
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-1272-2020 (May 14, 2020) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1272-2020 to see it in context.
  • Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA